Optimising the dose of capecitabine in metastatic breast cancer: Confused, clarified or confirmed?

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2145-2152

  Zielinski, C ^a,b   Gralow, J ^c   Martin, M ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Central European Cooperative Oncology Group Austria   (Austria)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Capecitabine; Dose modification; Dose reduction; Metastatic breast cancer; Therapeutic index

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PACLITAXEL;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION;

EID: 77958466863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq069     Document Type: Review

References (41)

1. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26(10): 1642-1649.
2. Gralow J, Rugo H, Gradishar W et al. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer 2008; 8(1): 33-37.
3. Mackean M, Planting A, Twelves C et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16(9): 2977-2985.
4. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18(6): 1337-1345.
5. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26(13): 2118-2123.
6. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17(2): 485-493.
7. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92(7): 1759-1768.
8. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14(8): 1227-1233.
9. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40(4): 536-542.
10. Largillier R, Fumoleau P, Clippe C et al. Capecitabine (X) monotherapy after anthracycline and taxane failure in metastatic breast cancer (MBC): long-term survival data. Ann Oncol 2006; 17(Suppl 9): ix74 (Abstr 161P).
11. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
12. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25(33): 5210-5217.
13. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2 positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
14. Hortobagyi GN, Perez E, Vrdoljak E et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials ASCO 2008 Breast Cancer Symposium (Abstr 186).
15. Mavroudis D, Ardavanis A, Boukovinas I et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. J Clin Oncol 2006; 24(18S): 658.
16. Osako T, Ito Y, Takahashi S et al. Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer. Tumori 2007; 93(2): 129-132.
17. Sezgin C, Kurt E, Evrensel T et al. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. South Med J 2007; 100(1): 27-32.
18. Hennessy BT, Gauthier AM, Michaud LB et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16(8): 1289-1296.
19. Blum JL, Jones SE, Buzdar AU. on behalf of the Xeloda Breast Cancer Study Group. Capecitabine in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose modification. Eur J Cancer 2001; 37 (Suppl 6): 190 (Abstr 693).
20. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12(9): 1247-1254.
21. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23(10): 2155-2161.
22. Stockler MR, Sourjina T, Grimison P et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007; 25(18S): 1031.
23. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27(15S): 42s (Abstr 1005).
24. Kaufmann M, Sütterlin MW, Schrader I et al. MoniCa: a multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39). Eur J Cancer Suppl 2009; 7: 260 (Abstr 5002).
25. Debled M, Madranges N, Trainaud A et al. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? Oncology 2009; 77: 318-327.
26. Yap YS, Kendall A, Walsh G et al. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer-how low can you go? Breast 2007; 16(4): 420-424.
27. O'Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc Am Soc Clin Oncol 2000; 19: (Abstr 400).
28. O'Shaughnessy JA. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function. Ann Oncol 2002; 13(6): 983.
29. Rossi D, Alessandroni P, Catalano V et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer 2007; 7(11): 857-860.
30. El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005; 14(5): 368-374.
31. Andreetta C, Puppin C, Minisini A et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 2009; 20(2): 265-271.
32. Martin M, Calvo L, Martinez N et al. Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC). J Clin Oncol 2009; 27(15s): 1086.
33. Saeki T, Kimura T, Toi M, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer 2006; 13(1): 49-57.
34. Watanabe T, Katsumata N, Sasaki Y et al. A multicenter phase II trial of XelodaTM (capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20: (Abstr 1991).
35. Kusama M, Nomizu T, Aogi K et al. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 2009 [Epub ahead of print].
36. Traina T, Theodoulou M, Dugan U et al. A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study. J Clin Oncol 2008; 26 (Suppl): (66s Abstr 1101).
37. Traina TA, Theodoulou M, Feigin K et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008; 26(11): 1797-1-802.
38. Levy E, Pierga J, Largillier R et al. Randomized study evaluating an alternative schedule of capecitabine (X) as monotherapy for metastatic breast cancer (MBC): safety and pharmacokinetic (PK) results. ASCO Breast Cancer Symposium 2008 (Abstr 188).
39. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27(12): 1999-2006.
40. Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006; 12(18): 5496-5502.
41. Ribelles N, López-Siles J, Sánchez A et al. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. Curr Drug Metab 2008; 9(4): 336-343.